This Pharmaceutical Manufacturer Considers Rs 40 Crore Buyback of 16 Lakh Shares at Rs 250 Each; Stock Gains Over 2%

DSIJ Intelligence/ 27 Apr 2026 /Categories: Mindshare, Trending

Join Us

Follow Us Select DSIJ as preferred on

This Pharmaceutical Manufacturer Considers Rs 40 Crore Buyback of 16 Lakh Shares at Rs 250 Each; Stock Gains Over 2%

Jagsonpal Pharmaceuticals secures approval to buy back up to 16 lakh equity shares; aims to enhance shareholder value

✨ AI Powered Summary

The Indian equity markets are trading in the green on Monday, with the Nifty 50 at 24,037.75, up 139.80 points or 0.58 per cent. Pharma stocks are also witnessing buying interest, with the Nifty Pharma index rising 2.56 per cent during the session. Amid this positive momentum, Jagsonpal Pharmaceuticals was trading at Rs 203.48, up 2.15 per cent, following a recent corporate development.

Every portfolio needs a growth engine. DSIJ’s Flash News Investment (FNI) provides weekly stock market insights and recommendations, tailored for both short-term traders and long-term investors. Download PDF Service Note Here

Jagsonpal Pharmaceuticals Buyback Update

Jagsonpal Pharmaceuticals has announced that shareholders have approved the company’s proposal to buy back equity shares, marking a key milestone in its capital allocation strategy.

Earlier, on March 12, 2026, the Board had proposed a buyback of up to 16 lakh equity shares at a price of Rs 250 per share, aggregating to a total consideration of up to Rs 40 crore. The shareholder approval for this proposal was received on April 27, 2026.

The company stated that the buyback is aimed at optimising capital structure, improving earnings per share, and delivering long-term value to shareholders.

Jagsonpal Pharmaceuticals Strategic Significance

Management highlighted that the endorsement by shareholders reflects continued investor confidence in Jagsonpal’s strategic direction, financial discipline, and long-term growth prospects.

The buyback is also aligned with the company’s broader objective of balancing growth investments with shareholder returns. The timeline, record date, and further implementation details are expected to be communicated separately in due course.

About Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals is a Delhi-based pharmaceutical company with over four decades of presence in the Indian pharma market. The company has a strong portfolio across therapeutic areas such as gynaecology, orthopaedics, dermatology, and childcare.

It has built a niche position with more than 20 brands ranked among the top five in their respective molecule categories and has a pan-India sales presence supported by over 1,000 professionals.